FrancophonIA/ELRC3.0 huggingface dataset:
English: Denmark Actavis Nordic A/S, Hammervej 7, DK-2970 Hørsholm, Denmark
Latvian: Actavis Nordic A/S, Hammervej 7, DK-2970 Hørsholm, Denmark
English: Eli Lilly and Company Ltd. Kingsclere Road, Basingstocke RG216XA Hampshire, UK
Latvian: Kingsclere Road, Basingstocke RG216XA Hampshire, UK
English: Mirtazapin Arrow 30 mg
Latvian: MIRTAZAPINA RIMAFAR 30 mg
English: GlaxoSmithKline GmbH & Co. KG Theresienhoehe 11
Latvian: GlaxoSmithKline GmbH & Co.
English: Mirtaron 45mgFilmtabletten
Latvian: Mirtaron 45mg-Filmtabletten 45mg
English: Dispersable tablet
Latvian: Putojošā tablete
English: Selvi Laboratorio Bioterapico S.p.A.
Latvian: Selvi Laboratorio Bioterapico S.p.A. Via Procoio, 28
English: Denmark Ratiopharm GmbH, Grat-Arco-Strasse 3, D-89079 Ulm, Germany
Latvian: Ratiopharm GmbH, Grat-Arco-Strasse 3, D-89079 Ulm, Germany
English: Prolonged relaesed capsule, hard
Latvian: Ilgstošās darbības mīkstās kapsulas
English: Fluoxistad 20mg-Kapseln 20mg
Latvian: Fluoxistad 20mg-Kapseln
English: Luxembourg EUROGENERICS N.V. Heizel Esplanade B 22 B-1020 BRUSSEL, Belgium
Latvian: Heizel Esplanade B 22 B-1020 BRUSSEL, Belgium
English: Zoloft Loesungskonzentrat
Latvian: Zoloft Loesungskonzentrat 20 mg
English: Bruxelles, Belgium
Latvian: Dublin, Ireland
English: Reboxetin Pharmacia 2 mg
Latvian: Reboxetin Pharmacia
English: Fluoxetin-TEVA 20 mg Kapseln
Latvian: Fluoxetin-TEVA 20 mg Kapseln 20 mg
English: Denmark H. Lundbeck A/S, Ottiliavej 7-9, DK2500 Valby, Denmark
Latvian: H. Lundbeck A/S, Ottiliavej 7-9, DK2500 Valby, Denmark
English: Lithuania Eli Lilly Holdings Limited, Kingsclere Road, Basing Stoke, Hampshire, RG21
Latvian: Eli Lilly Holdings Limited, Kingsclere Road, Basing Stoke, Hampshire, RG21 6XA, United Kingdom
English: Citalopram AL 40 mg Filmtabletten 40 mg
Latvian: Citalopram AL 40 mg Filmtabletten
English: Mianserine MG Pharma 10 mg
Latvian: Mianserine MG Pharma
English: Fluoxetine Teva Pharma 20 mg
Latvian: Fluoxetine Teva Pharma
English: Denmark HEXAL A/S, Kanalholmen 8-12, DK2650 Hvidovre, Denmark
Latvian: Norvēģija Hexal A/S, Kanalholmen 8-12, DK2650 Hvidovre, Denmark
English: Norton Healthcare Ltd. Albert Basin Royal Docks, E 162QJ London, UK
Latvian: Albert Basin Royal Docks, E 162QJ London, UK
English: FLUVOXAMINA SÁNDOZ
Latvian: FLUVOXAMINA TEVA
English: MIRTAZAPIN /GENERICS
Latvian: MIRTAZAPIN /GENERICS 30/mg
English: Fluvoxaminemaleaat 50 mg, tablets
Latvian: Fluvoxaminemaleaat 50 mg, tablets 50 mg
English: Fluoxetin "Copyfarm" 20 mg
Latvian: Fluoxetin "Copyfarm"
English: Mirtaron 15mgFilmtabletten
Latvian: Mirtaron 15mg-Filmtabletten 15mg
English: Euplix 20 mg Filmtabletten
Latvian: Euplix 20 mg Filmtabletten 20 mg
English: Fluoxetine Ranbaxy 20 mg
Latvian: Fluoxetine Ranbaxy
English: Remergil 30mg Filmtabletten
Latvian: Remergil 30mg Filmtabletten 30 mg
English: Seroxat Filmtabletten 20 mg
Latvian: Seroxat 20mg-Filmtabletten 20mg
English: Sertralin STADA 100 mg
Latvian: SERTRALIN HEXAL 100 100 mg
English: Denmark Ratiopharm GmbH, Graft-Arco-Strasse 3, D-89079 Ulm, Germany
Latvian: Ratiopharm GmbH, Graft-Arco-Strasse 3, D-89079 Ulm, Germany
English: Mirtazza 15 mg Filmtabletten
Latvian: Mirtazza 15 mg Filmtabletten 15 mg
English: Cipralex 15 mg Filmtabletten 15 mg
Latvian: Cipralex 15 mg Filmtabletten
English: MIRTAZAPINA MERCK
Latvian: Mirtazapina KRKA
English: Alfred E. Tiefenbacher (GmbH & Co. KG) Van-der-Smissen-Str. 1
Latvian: ALFRED E. TIEFENBACHER (GMBH & CO.
English: Cipramil 40 mg/ml, drops oral drops, solution Oral use
Latvian: Cipramil 40 mg/ml, drops
English: Alfred E. Tiefenbacher GmbH & Co. KG, Van-der-Smissen-Strasse 1, 22767 HAMBURG, Germany
Latvian: KG, Van-der-Smissen-Strasse 1, 22767 HAMBURG, Germany
English: Fluoxetin "Alpharma" 20 mg
Latvian: Fluoxetin "Alpharma"
English: Citalopram AL 20 mg Filmtabletten 20 mg
Latvian: Citalopram AL 20 mg Filmtabletten
English: Fluoxetine Merck 20 mg, capsules
Latvian: Fluoxetine Merck 20 mg, capsules 20 mg
English: Cipralex 10 mg Filmtabletten 10 mg
Latvian: Cipralex 10 mg Filmtabletten
English: Rowex Ltd, Bantry, Co. Cork, Ireland Paroxetine
Latvian: Rowex Ltd, Bantry, Co.
English: Alfred E Tiefenbacher (GmbH & Co. KG) Van-der-Smissen Strasse 1 DE22767 Hamburg Tyskland (DEU)
Latvian: Van-der-Smissen Strasse 1 DE22767 Hamburg Tyskland (DEU)
English: Instituto Luso-Fármaco, Lda., Rua Dr. António Loureiro Borges n.º 3Arquiparque - Miraflores 1495-131 Algés Portugal
Latvian: António Loureiro Borges n.º 3Arquiparque - Miraflores 1495-131
English: Meat and offal: cattle: 22 days.
Latvian: 1 flakons Gaļa un blakusprodukti: liellopi: 22 dienas
English: Target species
Latvian: Subkutānai lietošanai
English: This summary was last updated on 14/03/2011.
Latvian: Šo kopsavilkumu pēdējo reizi atjaunināja 14/03/2011.
English: It is widespread in countries bordering the Mediterranean Sea.
Latvian: Tas ir plaši izplatīts valstīs pie Vidusjūras.
English: These reactions resolve spontaneously within two days to two weeks.
Latvian: Šīs reakcijas spontāni pāriet divu dienu līdz divu nedēļu laikā.
English: Afterward a single ‘booster' should be given every year to maintain the vaccine's effect.
Latvian: Pēc tam katru gadu jāievada vienreizēja pastiprinošā deva, lai saglabātu vakcīnas iedarbību.
English: CaniLeish is a vaccine.
Latvian: CaniLeish ir vakcīna.
English: The efficacy of vaccination in dogs already infected was not investigated and therefore cannot be recommended.
Latvian: Vakcinācijas efektivitāte jau inficētiem suņiem netika pētīta un tādēļ nav ieteicama.
English: The first injection can be given from six months of age, the second injection is given three weeks later and the third three weeks from the second one.
Latvian: Pirmo injekciju var ievadīt no sešu mēnešu vecuma, otro injekciju ievada trīs nedēļas vēlāk, trešo injekcijutrīs nedēļas pēc otrās.
English: It is available as a powder and solvent that is made up into suspension for injection.
Latvian: Tā ir pieejama kā pulveris un šķīdinātājs, no kuriem pagatavo injekciju suspensiju.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for CaniLeish to Virbac S.A. on 14/03/2011.
Latvian: Eiropas Komisija 14/03/2011 izsniedza CaniLeish reģistrācijas apliecību, kas derīga visā Eiropas Savienībā, uzņēmumam Virbac S.A.
English: A number of laboratory trials where dogs were submitted to experimental infection were also presented.
Latvian: Tika prezentēti arī vairāki laboratorijas pētījumi, kuros suņi tika eksperimentāli pakļauti infekcijai.
English: In the future, if the animals are exposed to Leishmania infantum parasite, the immune system will be able to respond more quickly.
Latvian: Turpmāk, ja dzīvnieki saskaras ar Leishmania infantum parazītu, imūnsistēma spēs veidot antivielas daudz ātrāk.
English: Infected dogs play a central role in the accidental transmission of parasites to humans.
Latvian: Inficētiem suņiem ir galvenā loma parazītu nejaušā pārnešanā uz cilvēkiem.
English: Other temporary signs commonly seen following vaccination can also occur such as hyperthermia (raised body temperature), apathy (lack of vitality) and digestive disorders lasting one to six days.
Latvian: Citas īslaicīgas parādības, ko parasti novēro pēc vakcinācijas, ir hipertermija (paaugstināta temperatūra), apātija (dzīvesprieka trūkums) un gremošanas traucējumi, kas ilgst vienu līdz sešas dienas.
English: The risk of vaccine-induced infection can be excluded since the vaccine does not contain parasites.
Latvian: Vakcīnas izraisīta infekcija ir izslēgta, jo vakcīna nesatur parazītus.
English: Allergic-type reactions are uncommon and if a dog shows signs of an allergic reaction, they should be given appropriate symptomatic treatment.
Latvian: Alerģiskas reakcijas novēro reti, un, ja suņiem ir alerģisku reakciju pazīmes, tiem jādod attiecīgs simptomus mazinošs līdzeklis.
English: Leishmania infantum is a parasite that causes leishmaniosis.
Latvian: Leishmania infantum ir parazīts, kas izraisa leišmaniozi.
English: After injection, some dogs can have moderate and temporary local reactions, such as swelling, nodule (hardening), pain on palpation or erythema (reddening).
Latvian: Pēc injekcijas dažiem suņiem var būt mērenas un īslaicīgas lokālas reakcijas, piemēram, tūska, mezgliņš (sabiezējums), sāpes palpējot vai eritēma (apsārtums).
English: Why has CaniLeish been approved?
Latvian: Kāpēc CaniLeish tika apstiprināta?
English: It contains Leishmania infantum excreted secreted proteins (ESP).
Latvian: Tā satur Leishmania infantum ekskretētas sekretētas olbaltumvielas (ESO).
English: CaniLeish is a vaccine that contains a number of proteins that are released from the Leishmania infantum parasite during its growth.
Latvian: CaniLeish ir vakcīna, kas satur vairākas olbaltumvielas, kuras izdalās no Leishmania infantum parazīta tā attīstības posmā.
English: Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
Latvian: Tajā ir paskaidrots, kā Veterināro zāļu komiteja (CVMP) novērtēja iesniegtos dokumentus, pirms sniegt ieteikumus par šīs vakcīnas lietošanu.
English: Dogs that have been infected may show no signs of infection, but some do (fever, hair and weight loss, skin sores) and in the latter case the outcome of active infection can be fatal.
Latvian: Inficētiem suņiem var nebūt novērojamas infekcijas pazīmes, taču dažiem tās var būt novērojamas (drudzis, spalvas izkrišana, svara zudums, ādas čūlas), un tādā gadījumā aktīvas infekcijas rezultāts var būt letāls.
English: What is CaniLeish?
Latvian: Kas ir CaniLeish?
English: The efficacy of the vaccine was studied in one main field trial that lasted for two years involving vaccinated and control dogs submitted to natural exposure to infection in zones where there is a high risk of infection.
Latvian: Vakcīnas iedarbīgums tika pētīts vienā lauka pamatpētījumā, kas ilga divus gadus un kurā vakcinētos un kontroles suņus pakļāva dabīgai infekcijas iedarbībai vietās, kur ir augsts infekcijas risks.
English: Other information about CaniLeish:
Latvian: Cita informācija par CaniLeish.
English: CaniLeish contains an ‘adjuvant' (a highly purified fraction of Quillaja saponaria) to enhance the immune response.
Latvian: CaniLeish satur “adjuvantu” (attīrītu Quillaja saponaria frakciju), kas paredzēts imūnreakcijas stimulēšanai.
English: The vaccine was generally well tolerated as shown by the absence of major adverse reactions.
Latvian: Šīs vakcīnas panesamība kopumā bija laba, un būtiskas sistēmiskas reakcijas netika novērotas.
English: In case of accidental self-injection, the advice of a doctor should be sought immediately.
Latvian: Nejaušas pašinjicēšanas gadījumā, nekavējoties vērsieties pie ārsta pēc palīdzības.
English: The detection of Leishmania infection using a rapid diagnostic test is recommended before vaccination.
Latvian: Pirms vakcinācijas ieteicams noteikt Leishmania infekciju, izmantojot ātro diagnostisko testu.
English: Veterinarians should assess the benefit-risk balance before vaccinating dogs in areas with little or no Leishmania infantum.
Latvian: Veterināriem jāizvērtē ieguvumu un riska samērs pirms suņu vakcinēšanas apgabalos, kuros Leishmania infantum nav izplatīta vai sastopama ļoti reti.
English: The parasite is transmitted from an infected dog to a non-infected dog by the bites of sand flies.
Latvian: Parazīts no inficēta suņa uz neinficētu suni tiek pārnests ar moskītu kodieniem.
English: After vaccination transient antibodies against leishmania detected by immunofluorescence antibody test (IFAT) may appear but do not reflect an active infection.
Latvian: Pēc vakcinācijas imunoflorescences antivielu testā (IFAT) var parādīties pārejošas antivielas pret leišmaniozi, taču tās neliecina par aktīvu infekciju.
English: The safety of the vaccine was studied in two main laboratory safety studies carried out in leishmania-free dogs (overdose and single and repeated administration) and one field trial.
Latvian: Vakcīnas drošums tika pētīts divos laboratorijas pamatpētījumos ar suņiem, kuri nebija inficēti ar leišmaniozi, (pārdozēšana un viena un atkārtota ievadīšana) un vienā lauka pētījumā.
English: The CVMP concluded that the benefits of CaniLeish outweigh the risks for the active immunisation of leishmania-negative dogs from six months of age to reduce the risk to develop an active infection and clinical disease after contact with Leishmania infantum and recommended that CaniLeish be given a marketing authorisation.
Latvian: CVMP secināja, ka ieguvumi no CaniLeish lietošanas attaisno riskus attiecībā uz ar leišmaniozi neinficētu suņu aktīvu imunizāciju no sešu mēnešu vecuma, lai samazinātu aktīvas infekcijas un klīniskas slimības risku pēc kontakta ar Leishmania infantum un ieteica izsniegt CaniLeish reģistrācijas apliecību.
English: When CaniLeish is given to dogs the immune system recognises the proteins as ‘foreign' and make defences against it.
Latvian: Ievadot CaniLeish suņiem, dzīvnieku imūnsistēma atpazīst vīrusu kā „svešu” un veido pret to antivielas.
English: CaniLeish is used to vaccinate dogs from six months of age to reduce the risk of developing an active infection and clinical disease after contact with Leishmania infantum.
Latvian: CaniLeish lieto suņu vakcinēšanai no sešu mēnešu vecuma, lai samazinātu aktīvas infekcijas un klīniskas slimības risku pēc kontakta ar Leishmania infantum.
English: The studies showed that the vaccine is safe for both leishmania-negative and leishmania-infected dogs.
Latvian: Veiktajos pētījumos tika pierādīts, ka vakcīna ir droša gan ar leišmaniozi neinficētiem, gan inficētiem suņiem.
English: Canine vaccine against Leishmania infantum adjuvanted
Latvian: Vakcīna ar adjuvantu suņiem pret Leishmania infantum
English: The benefit of the vaccination was assessed in zones with a high risk of infection where it has been shown in leishmania free dogs to decrease the risk of developing an active infection and a symptomatic disease after contact with the parasite.
Latvian: Dzīvnieku ieguvumi, lietojot vakcīnu, tika izvērtēti zonās ar augstu infekcijas risku, kur novēroja, ka ar leišmaniozi neinficētiem suņiem vakcīna samazina aktīvas infekcijas risku un simptomātisku slimību pēc kontakta ar parazītu.
English: What is the risk associated with CaniLeish?
Latvian: Kāds pastāv risks, lietojot CaniLeish?
English: CaniLeish is to be used only in ‘leishmania-negative' dogs.
Latvian: CaniLeish lieto tikai ar leišmaniozi neinficētiem suņiem.
English: What benefit has CaniLeish shown during the studies?
Latvian: Kāds ir CaniLeish iedarbīgums šajos pētījumos?
English: The vaccine is given to dogs as three injections, three weeks apart, under the skin.
Latvian: Vakcīnu suņiem ievada ar trīs injekcijām zemādā, ievērojot trīs nedēļu intervālu starp injekcijām.
English: How does CaniLeish work?
Latvian: Kā darbojas CaniLeish?
English: The number of dogs developing an active infection and a symptomatic disease was significantly reduced in the vaccinated group.
Latvian: Vakcinēto suņu grupā bija ievērojami mazāks to suņu īpatsvars, kuriem attīstījās aktīva infekcija un simptomātiska slimība.
English: In dogs developing leishmaniosis (active infection or disease) despite vaccination, proceeding with vaccine injections showed no benefit.
Latvian: Netika pierādīts labums no vakcīnas ievadīšanas tādiem suņiem, kuriem attīstījusies leišmanioze (aktīva infekcija un/vai slimība), neskatoties uz vakcīnas ievadīšanu.
English: How has CaniLeish been studied?
Latvian: Kā noritēja CaniLeish izpēte?
English: What is CaniLeish used for?
Latvian: Kāpēc lieto CaniLeish?
English: The company presented data from three main studies involving over 3,000 patients.
Latvian: Uzņēmums iesniedza datus no trim pamatpētījumiem, kuros piedalījās 3000 pacienti.
English: What is Plivensia?
Latvian: Kas ir Plivensia?
English: The main measure of effectiveness was a reduction in symptoms of 20% or more, based on a standard rating score (ACR-20), after 16 weeks of treatment.
Latvian: Galvenais efektivitātes rādītājs bija simptomu samazinājums par vismaz 20 %, mērot ar standarta vērtēšanas rādītāju (ACR-20), pēc 16 ārstēšanas nedēļām.
English: In its letter notifying the Agency of the withdrawal of the application, the company stated that, given the need for additional clinical data and the fact that other treatments blocking the action of interleukin-6 are available, it wishes to prioritise other programs in its portfolio.
Latvian: Vēstulē, kurā uzņēmums informēja aģentūru par pieteikuma atsaukšanu, tas paziņoja, ka, tā kā ir vajadzīgi papildu klīniskie dati un ir pieejami citi interleikīnu-6 darbību bloķējoši ārstēšanas līdzekļi, uzņēmums vēlētos lielāku uzmanību pievērst citām programmām tā portfelī.
English: The company informed the CHMP that it will discontinue the ongoing long-term extension study with Plivensia in patients with rheumatoid arthritis.
Latvian: Uzņēmums informēja CHMP, ka tas pārtrauks notiekošo ilgtermiņa pagarinājuma pētījumu par Plivensia lietošanu reimatoīdā artrīta pacientiem.
English: Plivensia is a medicine that contains the active substance sirukumab.
Latvian: Plivensia ir zāles, kas satur aktīvo vielu sirukumabu.
English: It was to be available as a solution for injection in pre-filled pens and syringes (50 mg).
Latvian: Tās ir pieejamas kā šķīdums injekcijām pildspalvveida pilnšļircēs un pilnšļircēs (50 mg).
English: 10 November 2017 EMA/727596/2017 EMEA/H/C/004165
Latvian: EMA/727596/2017
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Latvian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom2017. gada 10. novembris EMA/727596/2017
English: Plivensia was to be used with methotrexate (a DMARD) or alone if the patient could not take methotrexate.
Latvian: Plivensia bija paredzēts lietot kopā ar metotreksātu (DMARD) vai atsevišķi, ja pacients nevar lietot metotreksātu.
English: Withdrawal of the marketing authorisation application for Plivensia (sirukumab)
Latvian: Plivensia (sirukumabs) reģistrācijas apliecības pieteikuma atsaukšana
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that, because of lack of proven long-term safety, the benefits of Plivensia did not outweigh its risks, and that further studies were needed.
Latvian: Tāpēc atsaukšanas brīdī CHMP uzskatīja, ka Plivensia sniegtie ieguvumi neatsver to radīto risku, jo nav pierādīts to drošums, un ir nepieciešami turpmāki pētījumi.
English: The third study compared Plivensia with adalimumab (a monoclonal antibody targeting a chemical messenger called tumour necrosis factor - TNF) in patients who could not take methotrexate or whose condition had not responded adequately to methotrexate; the study looked at the improvement in how patients' joints worked (based on a standard rating score called DAS28-ESR) after 24 weeks of treatment.
Latvian: Trešajā pētījumā Plivensia tika salīdzinātas ar adalimumabu (monoklonālu antivielu, kas vērsta pret ķīmisku signālvielu, ko dēvē par audzēja nekrozes faktoru jeb TNF) pacientiem, kuri nevarēja lietot metotreksātu vai kuriem nebija pietiekamas atbildes reakcijas uz metotreksātu; pētījumā tika vērtēts pacientu locītavu darbības uzlabojums (pamatojoties uz standarta vērtēšanas rādītāju DAS28-ESR) pēc 24 ārstēšanas nedēļām.
English: The active substance in Plivensia, sirukumab, is a monoclonal antibody, a type of protein which has been designed to block a molecule called interleukin-6.
Latvian: Plivensia aktīvā viela sirukumabs ir monoklonāla antiviela - olbaltumvielas veids, kas izstrādāta, lai bloķētu molekulu, ko dēvē par interleikīnu-6.
English: On 26 October 2017, Janssen-Cilag International NV officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Plivensia, for the treatment of rheumatoid arthritis.
Latvian: Uzņēmums Janssen-Cilag Internatonal NV 2017. gada 26. oktobrī oficiāli informēja Cilvēkiem paredzēto zāļu komiteju (CHMP) par savu lēmumu atsaukt Plivensia reģistrācijas apliecības pieteikumu.
English: By blocking interleukin-6, sirukumab reduces inflammation and other symptoms associated with rheumatoid arthritis.
Latvian: Bloķējot interleikīnu-6, sirukumabs mazina iekaisumu un citus ar reimatoīdo artrītu saistītus simptomus.
English: Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal the CHMP had some concerns and was of the provisional opinion that Plivensia could not have been approved for the treatment of moderate to severe rheumatoid arthritis.
Latvian: Pamatojoties uz izskatītajiem datiem un uzņēmuma atbildēm uz CHMP jautājumu sarakstiem, atsaukšanas brīdī CHMP bija daži iebildumi, un CHMP tobrīd provizoriski atzina, ka Plivensia nevarēja apstiprināt vidēji smaga līdz smaga reimatoīdā artrīta ārstēšanai.
English: The medicine was to be used in patients when treatment with one or more medicines known as disease-modifying anti-rheumatic drugs (DMARDs) had not worked well enough or had led to troublesome side effects.
Latvian: Šīs zāles bija paredzēts lietot pacientiem, kuriem ārstēšana ar vienu vai vairākām zālēm, kas sauktas par slimību modificējošiem pretreimatisma līdzekļiem (DMARD), nav bijusi pietiekami iedarbīga vai ir izraisījusi uztraucošas blakusparādības.
English: How does Plivensia work?
Latvian: Kā Plivensia darbojas?
English: The CHMP's main concern was that the long-term safety of Plivensia had not been well characterised due to limitations in the design of the main studies.
Latvian: CHMP galvenais iebildums bija par to, ka pamatpētījumu plānojuma noteikto ierobežojumu dēļ nav pienācīgi raksturots Plivensia ilgtermiņa drošums.
English: Interleukin-6 is involved in causing inflammation and is found at high levels in the joints of patients with rheumatoid arthritis.
Latvian: Interleikīns-6 ir iesaistīts iekaisuma procesā, un pacientiem ar reimatoīdo artrītu tas augstā līmenī ir atrodams locītavās.
English: What was Plivensia expected to be used for?
Latvian: Kādam nolūkam bija paredzēts lietot Plivensia?
English: Plivensia was expected to be used in adults with moderate to severe rheumatoid arthritis, a disease that causes inflammation of the joints.
Latvian: Plivensia bija paredzēts lietot pieaugušajiem ar vidēji smagu līdz smagu reimatoīdo artrītu - slimību, kas izraisa locītavu iekaisumu.
English: Two studies compared Plivensia with placebo (a dummy treatment) in patients with moderate to severe rheumatoid arthritis for whom treatment with a DMARD or with an anti-TNF agent (another type of medicine for rheumatoid arthritis) had not worked well enough or had led to troublesome side effects.
Latvian: Divos pētījumos Plivensia tika salīdzinātas ar placebo (fiktīvu ārstēšanu) pacientiem ar vidēji smagu līdz smagu reimatoīdo artrītu, kuriem ārstēšana ar DMARD vai anti-TNF līdzekļiem (cita veida zālēm reimatoīdā artrīta ārstēšanai) nav bijusi pietiekami iedarbīga vai ir izraisījusi uztraucošas blakusparādības.
English: These changes returned to normal within two weeks.
Latvian: Šīs izmaiņas normalizējās divu nedēļu laikā.
English: The absolute bioavailability amounts to approximately 91%.
Latvian: Absolūtā biopieejamība ir apmēram 91%.
English: Avalox was initially approved in June 1999.
Latvian: Avalox pirmo reizi tika reģistrēta 1999. gada jūnijā.
English: 5 - 10 days
Latvian: 5 - 10 dienas
English: This Mutual Recognition variation procedure was started on 7 December 2006.
Latvian: Šī savstarpējās atzīšanas izmaiņu procedūra tika uzsākta 2006. gada 7. decembrī.
English: It is important that you complete the course of treatment, even if you begin to feel better after a few days.
Latvian: Ir svarīgi pabeigt ārstēšanas kursu, pat ja Jūs jūtaties labāk jau pēc dažām dienām.
English: Possible side effects).
Latvian: Iespējamās blakusparādības).
English: - If you are under 18 years of age.
Latvian: Ja esat jaunāks par 18 gadiem
English: In this situation adequate therapeutic measures should be initiated immediately.
Latvian: Šai gadījumā nekavējoties jāveic piemēroti terapeitiskie pasākumi.
English: Therefore it is recommended that these medicines are not used together.
Latvian: Tāpēc ieteicams šīs divas zāles nelietot kopā.